XML 33 R24.htm IDEA: XBRL DOCUMENT v3.22.1
REVENUE (Tables)
3 Months Ended
Mar. 31, 2022
Disaggregation of Revenue [Line Items]  
Financing Receivable, Allowance for Credit Loss [Table Text Block] The rollforward for the allowance for credit losses for the three months ended March 31, 2022 is as follows:
Accounts ReceivableUnbilled ServicesNote and Other ReceivablesTotal
Balance as of December 31, 2021$21.5 $13.9 $0.7 $36.1 
Plus, credit loss expense(0.4)— — (0.4)
Less, write offs1.7 0.7 — 2.4 
Balance as of March 31, 2022$19.4 $13.2 $0.7 $33.3 
Contract with Customer, Asset and Liability [Table Text Block]
March 31, 2022December 31, 2021
Dx accounts receivable$1,155.2 $1,193.8 
DD accounts receivable1,103.8 1,089.2 
Less DD allowance for doubtful accounts(19.4)(21.5)
Accounts receivable$2,239.6 $2,261.5 
Gross unbilled services$813.2 $730.8 
Less reserve for unbilled services(13.2)(14.0)
Unbilled services$800.0 $716.8 
Unearned revenue$556.0 $558.5 
Disaggregation of Revenue [Table Text Block]
The Company's revenues by segment and by payers/customer groups for the three months ended March 31, 2022, and 2021, were as follows:
For the Three Months Ended March 31, 2022For the Three Months Ended March 31, 2021
North AmericaEuropeOtherTotalNorth AmericaEuropeOtherTotal
Payer/Customer
Dx
   Clients17 %— %— %17 %19 %— %— %19 %
   Patients%— %— %%%— %— %%
   Medicare and Medicaid%— %— %%%— %— %%
   Third party35 %— %— %35 %34 %— %— %34 %
Total Dx revenues by payer63 %— %— %63 %65 %— %— %65 %
DD
Pharmaceutical, biotechnology and medical device companies17 %13 %%37 %21 %10 %%35 %
Total revenues80 %13 %%100 %86 %10 %%100 %
Revenues in the U.S. were $3,000.5 (76.9%) and $3,472.5 (83.4%) for the three months ended March 31, 2022, and 2021, respectively.
DD Contract costs
Capitalized Contract Cost [Table Text Block]
March 31, 2022December 31, 2021
Sales commission assets$38.8 $36.2 
Deferred contract fulfillment costs14.9 14.4 
Total$53.7 $50.6